Helen Hsu

Helen Hsu is a seasoned Strategy Consultant with extensive expertise in the pharmaceuticals industry and hospital environments, specializing in translational research, clinical trial monitoring, and medical affairs. Her primary focus lies within oncology research with a proven track record of success.

Helen holds an MD in Medicine as an Honor Graduate from Southeastern University Medical School, complemented by an MS in Molecular Biology and Clinical Lab Management from Michigan State University, showcasing her strong educational background in the medical and scientific fields.

Throughout her career, Helen has held various key positions in reputable organizations. She has served as a Sr. Medical Director of Clinical Development at Epizyme, Executive Director at Evergrande Health Research Institute, General Manager of the Pharmaceutical Business Center at EVG Brigham and Women's Hospital/DFCI's International Cancer Hospital in China, Director of the Oncology Research Program at Eastern Maine Medical Center, and Acting Medical Director of Translational Research at Lafayette Family Cancer Center, among others.

With her wealth of experience, Helen has also contributed to well-known pharmaceutical companies such as Boehringer Ingelheim Pharmaceuticals and Novartis Consumer Health in roles such as Medical Director of Medical Affairs, Senior Associate Director of Clinical Research, and Medical Affairs Manager, demonstrating her versatility across different sectors of the pharmaceutical industry.

Prior to her industry roles, Helen gained valuable research experience as a Research Fellow and Project Leader at NorthShore University HealthSystem, a Research Scientist at Albert Einstein College of Medicine, and a Clinical Research Scientist at GlaxoSmithKline, highlighting her comprehensive understanding of scientific research and development.

Helen Hsu's background exemplifies a deep-rooted passion for advancing healthcare through strategic consulting and impactful contributions to the pharmaceutical and medical sectors, reinforcing her reputation as a trusted expert in the field.